Maybe the Bahaman Stock Market Is Closed Today October 10, 2011March 25, 2017 Has Wall Street no respect for Christopher Columbus? The man took an insane risk, endured tremendous hardship, and discovered the Bahamas. And he didn’t get Aquaventure or his fourth night free. But if the stock market’s open, this site is open. I’ll spare you politics for a day, but offer two updates: BOREF I have not ordered this book, because the hardcover is $4,295 and the e-book costs $3,995 to download. I doubt the Borealis team has ordered it either. But they’re excited: Look at the author’s conclusions (which we share): 1: The motors being used now are for enthusiasts and are unsuitable for the competitive mass market. 2: AC Induction (asynchronous) motors will dominate for larger vehicles down the road – for the reasons we have given (cooling being a key one). And then he lists *one* advanced asynchronous motor technology: 2.3.1. Advanced asynchronous motor variant – Chorus Motors and we get a second mention: 2.4.4. In wheel motors for aircraft. ☞ I have no idea if this means all that Borealis hopes it does, or anything much at all. But Borealis does own Chorus and – based on what little I know of livestock – it’s better than a kick in the head. DVAX Guru: “Friday, they reported the data from diabetic patients in their hepatitis B vaccine trial. It is the first time data from diabetic patients has been studied prospectively. Their vaccine was dramatically superior to the currently approved vaccine at all time points. In particular, at the prespecified time point of comparison – 12 weeks with just one booster shot for DVAX and 32 weeks with two booster shots for the currently-approved vaccine – DVAX showed protection in 79% versus 11% in the currently approved vaccine group!” So it was much more effective and reached its effectiveness level much faster. “The diabetic issue is important because later this month, the CDC convenes to vote on whether to require that all diabetics be vaccinated for Hep B. The committee made such a proposal in June, but did not take it to a formal vote. The formal vote comes later this month and is almost certain to be ‘yes.’ Today’s data show DVAX to be the clear choice. DVAX’s only problem appears to be that it is a small cap stock in a bear market. I continue to expect significant appreciation over the next year as it gets approved and launched. Separately, DVAX recently received money from Astra Zeneca to move ahead on a program to treat asthma and has partnerships with Glaxo and Novartis, also in early human trials, showing that there is a nice pipeline behind its leading product for Hep B.” ☞ With hindsight, it would have been nicer to pay Friday’s $1.83 for DVAX, say, than $2.77. But as I previously reported, Guru says he agrees with this $8 valuation, so I sit pat.